Now Reading: NPPA caps cancer drug profit at 30%, prices may drop 70%
-
01
NPPA caps cancer drug profit at 30%, prices may drop 70%
The National Pharmaceuticals Pricing Authority (NPPA) has capped the profit margin on 137 non-scheduled cancer drugs at 30%. The decision, published in a gazette notification on Saturday, 17 October 2026, takes effect from 9 November 2026.
Retail prices of these life-saving drugs could fall by up to 70% from current levels. The government told the Supreme Court two days ago that the cap is expected to save patients about Rs 2,500 crore annually.
The recommendation came from an expert committee under the Directorate General of Health Services (DGHS), comprising oncologists, medical experts, hospital specialists and government officials. The list will be updated periodically. State drug controllers have been directed to monitor compliance by manufacturers, dealers, retailers, hospitals and medical institutions.
Indian Opinion Analysis
The price cap directly targets the high out-of-pocket expenditure that cancer patients face, since many of these 137 drugs are not in the National List of Essential Medicines and therefore had no price control until now. What remains unresolved is how manufacturers will adjust: they may absorb the margin cut or exit unprofitable products. The Supreme Court, which heard the matter on 15 October, has asked the government to reply by 27 October on why similar price controls are not applied to other drugs, signalling that the cap on cancer drugs alone may not settle the broader pricing debate.
Source: bhaskar.com
This brief was synthesised by AI from the source linked above. Methodology and corrections.
